David Parkinson

Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA.

Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.

Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.

Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD.

Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD.

The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX.

US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD.

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA.

The Multiple Myeloma Research Foundation, Inc. provides funding for research on myeloma treatment. It provides funding to laboratories worldwide, including compounds and approaches in clinical trials and pre-clinical studies. The firm also facilitates clinical trials through their affiliate organization, the Multiple Myeloma Research Consortium. The company was founded by Karen E. Andrews and Kathryn E. Giusti in 1998 and is headquartered in Norwalk, CT.

Multiple Myeloma Research Foundation, the mission of the MMRF is to accelerate the development of novel and combination treatments for patients with multiple myeloma by promoting and facilitating collaborative research between industry and academia. The MMRC is led by an exceptional Leadership Team, including a full scientific and clinical staff, which is headquartered in Norwalk, Conn

The International Society for Biological Therapy of Cancer operates as a professional society of influential scientists, academicians, researchers, clinicians, and government representatives. The non-profit company is based in Milwaukee, WI.

Ontario Institute for Cancer Research provides research on the prevention, early detection, diagnosis, and treatment of cancer. It offers Innovation programs, like cancer stem cell, innovation in target validation, and smarter imaging, Technology programs, like drug discovery, genome technologies, informatics and bio-computing, imaging translation, and tranformative pathology, and Translation programs. The company was founded by Calvin R. Stiller in December 2005 and is headquartered in Toronto, Canada.

Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA.

Pierian Biosciences LLC operates as a diagnostic development and laboratory service company. It offers ChemoINTEL, a functional multi-parametric chemosensitivity assay measuring the real-time kinetic molecular and morphologic apoptotic response in isolated tumor cells; and ImmunoINTEL, a flow cytometry-based platform delivering phenotypic characterization and quantitative functional interrogation of tumor and immune populations within a tumor sample and relevant tissues. The company is headquartered in Franklin, TN.